Pulse Biosciences (PLSE) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Pulse Biosciences (NASDAQ: PLSE) recently:

• 8/10/2026 – Pulse Biosciences was given a new $45.00 price target by Mizuho.
• 8/10/2026 – Pulse Biosciences had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $43.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Pulse Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/28/2026 – Pulse Biosciences had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 7/28/2026 – Pulse Biosciences was given a new $35.00 price target by Oppenheimer Holdings, Inc..
• 7/17/2026 – Pulse Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.